Related Experiment Video
Updated: May 15, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Epoch making development of new drugs for prostate cancer]
1Dept. of Strategic Investigation on Comprehensive Cancer Network, University of Tokyo, Tokyo, Japan.
Abstract:
Prostate cancer responds well to androgen depletion therapy(ADT). However, when ADT was initiated on advanced prostate cancer, many become Castration-Resistant Prostate Cancer(CRPC)within a few years. Thus, development of new agents against CRPC is warranted. At the 2012 ASCO Meeting, results from two global randomized trials were given a warm reception. One trial involved abiraterone acetate and the other MDV3100.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Prodrugs
Prodrugs help overcome...
Preclinical Development: Overview

